Overview
In the United States, peptides are not a distinct legal category — they are regulated as drugs under the Federal Food, Drug, and Cosmetic Act. A handful of peptide drugs (such as semaglutide, tirzepatide, and human growth hormone products) are FDA-approved and lawfully available only by prescription, while 'research' peptides such as BPC-157, TB-500, KPV, and MOTS-C have no FDA approval and cannot lawfully be marketed or sold for human use, even though they are not scheduled controlled substances and simple personal possession is not itself a federal crime. FDA has historically placed many of these peptides in 'Category 2' of its compounding bulk-substances policy, but in April 2026 it removed twelve peptides from that category and convened advisory-committee review, and in July 2026 an FDA panel voted in favor of allowing several of them to be compounded. Import of unapproved peptides remains a significant enforcement target, with CBP seizing bulk overseas shipments and FDA issuing large batches of warning letters to GLP-1 compounders and sellers.
Key Points
- Peptides sold as 'research chemicals' for human use, such as BPC-157, are treated by the U.S. government as unapproved new drugs rather than lawful dietary supplements or foods. [1]
- FDA maintains a 'Category 2' list of bulk drug substances nominated for pharmacy compounding that the agency has identified as potentially presenting significant safety risks, and many peptides were placed in that category under its interim compounding policies. [2]
- In April 2026 FDA announced the removal of twelve peptides from Category 2 and scheduled Pharmacy Compounding Advisory Committee meetings to consider adding peptides to the section 503A bulk drug substances list. [3]
- At its July 23-24, 2026 meeting, the Pharmacy Compounding Advisory Committee formally considered BPC-157, KPV, TB-500, and MOTS-C (free base and acetate forms) for inclusion on the 503A Bulks List, along with emideltide (DSIP) and Semax on the second day. [4]
- The FDA advisory panel voted in favor of loosening restrictions on four of the peptides it reviewed, though advisory committee votes are recommendations and are not binding on FDA. [5]
- For the GLP-1 weight-loss peptides, FDA ended the period of enforcement discretion that had allowed state-licensed pharmacies and physicians to compound semaglutide and tirzepatide injection products under section 503A once the shortages resolved, with corresponding 503B outsourcing-facility deadlines in March and May 2025. [6]
- FDA has pursued large-scale enforcement in this space, sending warning letters to more than 50 compounders, manufacturers and marketers of GLP-1 products in 2025. [7]
- Personal and commercial importation of unapproved peptides is actively interdicted: CBP officers at the Port of Cincinnati seized over 5,000 mis-manifested peptide shipments from China between December 2025 and March 2026, including retatrutide, semaglutide, tirzepatide, MOTS-C and semax. [8]
- Separately, federal law singles out human growth hormone: 21 U.S.C. 333(e) makes knowing distribution or possession with intent to distribute HGH for uses other than the treatment of a disease authorized by FDA a felony offense. [9]
- Research peptides such as BPC-157 and TB-500 are generally understood not to be scheduled under the federal Controlled Substances Act, so DEA scheduling does not apply to them; however, no primary DEA source confirming their unscheduled status was located during this research, and this point reflects inference from the fact that federal enforcement proceeds under FD&C Act drug-approval authority rather than the CSA. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)